28.17
0.42 (1.51%)
| Previous Close | 27.75 |
| Open | 28.42 |
| Volume | 3,732,225 |
| Avg. Volume (3M) | 6,341,818 |
| Market Cap | 20,161,300,480 |
| Price / Sales | 1.44 |
| Price / Book | 4.64 |
| 52 Weeks Range | |
| Earnings Date | 28 May 2026 |
| Operating Margin (TTM) | -4,823.84% |
| Diluted EPS (TTM) | -0.750 |
| Quarterly Revenue Growth (YOY) | -16.10% |
| Quarterly Earnings Growth (YOY) | -96.70% |
| Total Debt/Equity (MRQ) | 1.93% |
| Current Ratio (MRQ) | 33.47 |
| Operating Cash Flow (TTM) | -839.45 M |
| Levered Free Cash Flow (TTM) | -375.20 M |
| Return on Assets (TTM) | -10.73% |
| Return on Equity (TTM) | -12.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Roivant Sciences Ltd. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -5.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.0 |
| Average | -1.20 |
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 30.31% |
| % Held by Institutions | 83.49% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 35.00 (Citigroup, 24.25%) | Buy |
| Median | 34.00 (20.70%) | |
| Low | 30.00 (Guggenheim, 6.50%) | Buy |
| Average | 33.00 (17.15%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 28.18 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 04 Mar 2026 | 34.00 (20.70%) | Buy | 29.52 |
| 10 Feb 2026 | 33.00 (17.15%) | Buy | 27.35 | |
| Citigroup | 10 Feb 2026 | 35.00 (24.25%) | Buy | 27.35 |
| Guggenheim | 09 Feb 2026 | 30.00 (6.50%) | Buy | 27.67 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GLINE MATTHEW | - | 27.06 | -358,510 | -9,861,291 |
| SUKHATME MAYUKH | - | 27.06 | -217,321 | -5,981,338 |
| Aggregate Net Quantity | -575,831 | |||
| Aggregate Net Value ($) | -15,842,630 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 27.06 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SUKHATME MAYUKH | Officer | 31 Mar 2026 | Disposed (-) | 187,512 | 27.70 | 5,194,082 |
| GLINE MATTHEW | Officer | 31 Mar 2026 | Disposed (-) | 304,684 | 27.70 | 8,439,747 |
| SUKHATME MAYUKH | Officer | 30 Mar 2026 | Disposed (-) | 29,809 | 26.41 | 787,256 |
| SUKHATME MAYUKH | Officer | 30 Mar 2026 | Option execute | 58,391 | - | - |
| GLINE MATTHEW | Officer | 30 Mar 2026 | Disposed (-) | 53,826 | 26.41 | 1,421,545 |
| GLINE MATTHEW | Officer | 30 Mar 2026 | Option execute | 97,319 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |